Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects

European Journal of Clinical Pharmacology

Volumn 52, Issue 5, 1997, Pages 391-396

  Katsuki, H ^a   Nakamura, C ^a   Arimori, K ^a   Fujiyama, S ^b   Nakano, M ^a  

^a KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

CYP2C19; Genotype; Hydroxylation; Lansoprazole; Pharmacokinetic; Polymorhism

Indexed keywords

CYTOCHROME P450 ISOENZYME; LANSOPRAZOLE;

ADULT; ALLELE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DISPOSITION; DRUG HYDROXYLATION; DRUG METABOLISM; FEMALE; GENETIC POLYMORPHISM; HUMAN; MALE; MUTATION; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; MUTATION; OMEPRAZOLE; POLYMORPHISM, GENETIC;

EID: 0030878213     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050307     Document Type: Article

References (27)

1. Gonzalez FJ, Idle JR (1994) Pharmacogenetic phenotyping and senotyping. Present status und future potential. Clin Pharmacokinet 26: 59-70
2. Brosen K (1990) Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics. Clin Pharmcokinet 18: 220-239
3. Zanger UM, Vilbois F, Hardwick J, Meyer UA (1988) Absence of hepatic cytochrome P450bufl causes genetically deficient debrisoquine oxidation in man. Biochemistry 27: 5447-5454
4. Kuper A, Preisig R (1984) Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 26: 753-759
5. Alvan G, Bechtel P, Iselius L, Gundert-Remy U (1990) Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 39: 533-537
6. Sohn DR, Kusaka M, Ishizaki T, Shin SG, Jang IJ, Shin JG, Chiba K (1992) Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and interphenotypic differences in diazepam pharmacokinetics. Clin Pharmacol Ther 52: 160-169
7. Goldstein JA, Fuletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, Lasker JM, Ghanayem BI (1994) Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 33: 1743-1752
8. Wrighton SA, Stevens JC, Becker GW, VandenBranden M (1993) Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch Biochem Biophys 306: 240-245
9. de Morais SMF, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA (1994) Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46: 594-598
10. Inatomi N, Nagaya H, Takami K, Shino A, Satoh H (1991) Effects of a proton pump inhibitor, AG-1749 (lansoprazole), on reflux esophagitis and experimental ulcers in rats. Jpn J Pharmacol 55: 437-451
11. Nagaya H, Satoh H, Maki Y (1990) Possible mechanism for the inhibition of acid formation by the proton pump inhibitor AG-1749 in isolated canine parietal cells. J Pharmacol Exp Ther 252: 1289-1295
12. Barradell LB, Faulds D, McTavish D (1992) Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs 44: 225-250
13. Tateno M, Nakamura N (1991) Phase I study of lansoprazole (AG-1749) antiulcer agent-capsule form- Rinsho Iyaku 7: 51-62
14. Andersson T, Regardh CG, Dahl-Puustinen ML, Bertilsson L (1990) Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 12: 415-416
15. Andersson T, Miners JO, Veronese ME, Tassaneeyakul W, Meyer UA, Birkett D (1993) Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 36: 521-530
16. Chiba K, Kobayashi K, Manabe K, Tani M, Kamataki T, Ishizaki T (1993) Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4′-hydroxylation. J Pharmacol Exp Ther 266: 52-59
17. Pearce RE, Rodrigues AD, Goldstein JA, Parkinson A (1996) Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther 277: 805-816
18. Chang M, Dahl ML, Tybring G, Gotharson E, Bertilsson L (1995) Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 5: 358-363
19. Ieiri I, Kubota T, Urae A, Kimura M, Wada Y, Mamiya K, Yoshioka S, Irie S, Amamoto T, Nakamura K, Nakano S, Higuchi S (1996) Pharmacokinetics of omeprazole (a substrate of CYP2C19) und comparison with two mutant alleles, CYP2C19m1 in exon 5 and CYP2C19m2 in exon 4, in Japanese subjects. Clin Pharmacol Ther 59: 647-653
20. Aoki I, Okumura M, Yashiki T (1991) High-performance liquid chromatographic determination of lansoprazole and its metabolites in human serum and urine. J Chromatogr 571: 283-290
21. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA (1994) The major genetic defect responsible for the polymorphism of S-mephenytoin in human. J Biol Chem 269: 15419-15422
22. Gerloff J, Mignot A, Barth H, Heintze K (1996) Pharmacokinetics and absolute bioavailability of lansoprazole. Eur J Clin Pharmacol 50: 293-297
23. Landes BD, Flouvat B, Duchier J, Molinie P, Dellatolas F, Lemaire M (1993) Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity. Eur J Clin Pharmacol 45: 367-371
24. Andersson T, Miners JO, Veronese ME, Birkett DJ (1994) Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. Br J Clin Pharmacol 37: 597-604
25. Julima M, Inaba T, Kadar D, Kalow W (1985) Genetic polymorphism of mephenytoin p(4′)-hydroxylation: Difference between Orientals and Caucasians. Br J Clin Pharmacol 19: 483-487
26. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, Branch RA (1985) Interethnic differences in genetic polymorphism of debrisoquine and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 38: 402-408
27. Chang M, Tybring G, Dahl ML, Gotharson E, Sagar M, Seensalu R, Bertilsson L (1995) Interphenotype diferences in disposition and effect on gastrin levels of omeprazole-suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 39: 511-518